Intraoperative Detection of a Bronchial Carcinoid With a Radiolabeled Somatostatin Analog

CHEST Journal ◽  
2002 ◽  
Vol 121 (3) ◽  
pp. 985-988 ◽  
Author(s):  
Jaime A. Rodriguez ◽  
Michael O. Meyers ◽  
Tomas H. Jacome ◽  
Paul Failla ◽  
Lynn H. Harrison
Keyword(s):  
Somatostatin Analog ◽  
Bronchial Carcinoid ◽  
Intraoperative Detection ◽  
Radiolabeled Somatostatin Analog

scholarly journals Multiple gastric carcinoids associated with parietal cell hyperplasia: intraoperative detection with a radiolabeled somatostatin analog

2008 ◽  
Vol 11 (2) ◽  
pp. 123-126 ◽  
Author(s):  
Yoshinori Hosoya ◽  
Kiichi Satoh ◽  
Mitsugu Hironaka ◽  
Mitsuhiro Nokubi ◽  
Kentaro Kurashina ◽  
...  
Keyword(s):  
Parietal Cell ◽  
Somatostatin Analog ◽  
Cell Hyperplasia ◽  
Gastric Carcinoids ◽  
Intraoperative Detection ◽  
Radiolabeled Somatostatin Analog

Targeted radiopeptide therapy Re188-P2045 to treat neuroendocrine lung cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e20016-e20016
Author(s):  
Christopher Peter Adams ◽  
Wasif M. Saif
Keyword(s):  
Lung Cancer ◽  
Image Analysis ◽  
Cancer Patients ◽  
Lung Tumor ◽  
Somatostatin Receptor ◽  
Receptor Expression ◽  
Somatostatin Analog ◽  
Receptor Subtype ◽  
Lung Cancer Patients ◽  
Radiolabeled Somatostatin Analog

e20016 Background: : Despite the recent success of checkpoint inhibitors, there continues to be a significant medical need for lung cancer therapies that can be directed to the patients most likely to respond. Somatostatin receptor subtype 2 (SSTR2) is the most widely up-regulated subtype in both small and non-small cell lung cancers and is also expressed in tumoral (but not mature) blood vessels. Peptide targeted radiotherapy has advantages over traditional targeted therapies in that targeted tumor cells as well as surrounding cancer cells and supporting stroma are selectively killed. This study was conducted to determine the ability of Rhenium Re 188 P2045, a radiolabeled somatostatin analog specific for SSTR2 to both image (to select the most appropriate patients) and treat lung cancer patients who over-express somatostatin receptors. Methods: In an open label, single arm study, refractory lung cancer patients to standard of care therapy were identified by image analysis using Rhenium Re 188 P2045, a radiolabeled somatostatin analog. 25 Patients received the imaging dose of 10uCi of Re188 and 265ng of peptide by intravenous injection. Three patients were selected based on high SSTR expression levels to receive 30uCi of Re188 P2045 as a therapeutic dose 14 days after imaging. Patients were followed for 8 weeks post treatment. Results: The imaging study revealed a high density of expression of the somatostatin receptor in the lungs of patients. Patients in the imaging and therapeutic treatment groups reported no adverse advents or signs of toxicity. The image analysis using Re188 P2045 was compared to CT images and demonstrated accurate detection of lung tumor lesions. The images obtained using Re188 P2045 were of sufficiently high quality to enable identification of receptor expression at the tumor site as shown in Figures 1&2. Conclusions: Rhenium Re 188 P2045, a radiolabeled somatostatin analog, may be used to both identify and treat lung cancer tumors. The ability to image and dose patients with the same targeted molecule enables a personalized medicine approach and this highly targeted patient therapy may significantly improve treatment of tumors that over express somatostatin receptor.

scholarly journals Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma

Cancer ◽  
1999 ◽  
Vol 86 (8) ◽  
pp. 1621-1627 ◽  
Author(s):  
Jonathan W. Friedberg ◽  
Annick D. Van den Abbeele ◽  
Kathleen Kehoe ◽  
Samuel Singer ◽  
Christopher D. Fletcher ◽  
...  
Keyword(s):  
Somatostatin Analog ◽  
Radiolabeled Somatostatin Analog

scholarly journals Metastatic Malignant Paraganglioma Presenting as a Neck Mass Treated with Radiolabeled Somatostatin Analog

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Waqas Jehangir ◽  
Alexander Karabachev ◽  
Jackie Tsao ◽  
Christopher J. Anker ◽  
Sree Susmitha Garapati ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Survival Benefit ◽  
Randomized Clinical Trials ◽  
Tumor Response ◽  
Neck Mass ◽  
Tumor Burden ◽  
Alternative Therapies ◽  
Somatostatin Analog ◽  
Malignant Paraganglioma ◽  
Radiolabeled Somatostatin Analog

Paragangliomas are rare neuroendocrine tumors that arise from chromaffin-containing tissue. Surgical resection and/or radiation are used for locoregional disease, and reduction of tumor burden with systemic therapy is reserved for metastatic disease. Iobenguane I-131, somatostatin analog (octreotide), and Sunitinib are noncytotoxic options for treatment, while cyclophosphamide, vincristine, and dacarbazine (CVD) and temozolomide are often used as initial chemotherapy options as studies have shown that they offer some tumor response. However, there are no randomized clinical trials demonstrating prolonged survival with the use of chemotherapeutics in metastatic cases. Investigation of alternative therapies that provide survival benefit is thus necessary. We present a case of a 69-year-old female with metastatic malignant paraganglioma presenting as a left parapharyngeal neck mass, which metastasized after surgery, requiring radiation therapy for bony metastasis who was treated with a radioisotope somatostatin analog for disease progression.

scholarly journals Preoperative Detection of an ACTH-producing Small Bronchial Carcinoid with 111In-pentetoreotide (Somatostatin Analog) Scintigraphy

Haigan ◽  
2006 ◽  
Vol 46 (4) ◽  
pp. 375-378
Author(s):  
Teruhisa Takuwa ◽  
Seiki Hasegawa ◽  
Fumihiro Tanaka ◽  
Hiromi Wada
Keyword(s):  
Somatostatin Analog ◽  
Bronchial Carcinoid
Sign in / Sign up

Export Citation Format

Share Document